Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Siemens launches new bleeding risk assessment test

Siemens launches new bleeding risk assessment test

24th March 2010

Siemens has introduced a new testing product which allows clinicians to assess the risk of bleeding among patients undergoing certain therapies.

The science company’s new Innovance PFA P2Y test works in conjunction with its PFA-100 haemostasis measurement system to gauge the response of patients to P2Y12-receptor antagonist-based treatments.

This patient group is identified as being at a high risk of suffering major bleeding during and after surgery, with transfusions often required to mitigate the problem.

Siemens states that its product can help to prevent this thanks to its fast-acting nature and effectiveness among a wide range of patients.

It added: “Unlike other P2Y12-receptor blockage inhibitor tests [such as] ADP-induced aggregometry, Innovance PFA P2Y provides a universal cut-off and instructions for easy PFA result interpretation.”

Earlier this month, the company released a new Brahms assay product which detects serum levels of the protein procalcitonin in order to diagnose the onset of sepsis.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.